Platelet reactivity and formation of platelet-monocyte complexes in patients with chronic obstructive pulmonary disease (COPD)
Completed
- Conditions
- COPD chronic obstructive pulmonary disease100110821000643610003216
- Registration Number
- NL-OMON42526
- Lead Sponsor
- ongziekten
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
In order to be eligible to participate in this study the COPD subjects must meet all of the following criteria:
• >40 years
• Bronchus obstruction detected by spirometry: FEV1/FVC ratio < 70% and postbronchodilatory FEV1<80% (COPD Gold II-IV) and clinical diagnosis confirmed by a pulmonologist.
• >=10 pack years of smoking
Exclusion Criteria
• Use of aspirin or other platelet function inhibitors
• Asthma
• Chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE)
• Malignancies
Regarding the control subjects the inclusion criteria described above do not apply, however the exclusion criteria do apply.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Parameters are platelet reactivity (platelet expression of the platelet<br /><br>activation marker CD62P (P-selectin) and activated fibrinogen receptor (aIIbβ3)<br /><br>upon stimulation with different platelet agonists), platelet-monocyte<br /><br>complexes, soluble markers of platelet activation and inflammatory cytokines<br /><br>and the relation of platelet activation to GOLD classification, exacerbation<br /><br>rate, smoking and lung function. </p><br>
- Secondary Outcome Measures
Name Time Method <p>See primairy outcomes. </p><br>